Search
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.
Amniotic Epithelial Cells
go.drugbank.com/drugs/DB15868InvestigationalAmniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus. These cells are potential candidates for allogeneic cell ...
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalBoehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks. Olcegepant is undergoing phas...
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...
EDP1815
go.drugbank.com/drugs/DB16486InvestigationalEDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal beha...
Astodrimer
go.drugbank.com/drugs/DB11854InvestigationalAstodrimer has been used in trials studying the treatment and prevention of Bacterial Vaginosis. It is a lysine-based dendrimer with naphthalene disulfonic acid surface groups.
INCB13739
go.drugbank.com/drugs/DB05064InvestigationalINCB13739 is developed as a new treatment for type 2 diabetes. It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the d...
Ronacaleret
go.drugbank.com/drugs/DB05255InvestigationalRonacaleret is a calcium-sensing receptor antagonist.
SGN-15
go.drugbank.com/drugs/DB05818InvestigationalSGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxo...
Anpocogin
go.drugbank.com/drugs/DB06552InvestigationalRecombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.